NCT04848597

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary (CUP)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.

Detailed description

Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable adverse reactions, patient death or withdrawal informed agree.After treatment, the patients was followed up every 9 weeks for follow-up treatment and survival.

Conditions

• Cancer of Unknown Primary

Interventions

Type	Name	Description
DRUG	Recombinant humanized anti-PD-1 monoclonal antibody injection	200mg , once every 3 weeks

Timeline

• Start date: 2021-05-13
• Primary completion: 2023-05-01
• Completion: 2023-05-03
• First posted: 2021-04-19
• Last updated: 2022-04-20

Locations

1 site across 1 country: China